Abstract
G protein-coupled receptor kinases (GRKs) constitute seven subtypes of serine/threonine protein kinases that specifically recognize and phosphorylate agonist-activated G protein-coupled receptors (GPCRs), thereby terminating the GPCRs-mediated signal transduction pathway. Recent research shows that GRKs also interact with non-GPCRs and participate in signal transduction in non-phosphorylated manner. Besides, GRKs activity can be regulated by multiple factors. Changes in GRKs expression have featured prominently in various tumor pathologies, and they are associated with angiogenesis, proliferation, migration, and invasion of malignant tumors. As a result, GRKs have been intensively studied as potential therapeutic targets. Herein, we review evolving understanding of the function of GRKs, the regulation of GRKs activity and the role of GRKs in human malignant tumor pathophysiology.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Pitcher JA, Freedman NJ, Lefkowitz RJ. G protein-coupled receptor kinases. Annu Rev Biochem. 1998;67:653–92.
Manglik A, Kruse AC. Structural basis for G protein-coupled receptor activation. Biochem-Us. 2017;56:5628–34.
Liu Y, An S, Ward R, Yang Y, Guo XX, Li W, et al. G protein-coupled receptors as promising cancer targets. Cancer Lett. 2016;376:226–39.
Metaye T, Gibelin H, Perdrisot R, Kraimps JL. Pathophysiological roles of G-protein-coupled receptor kinases. Cell Signal. 2005;17:917–28.
Komolov KE, Benovic JL. G protein-coupled receptor kinases: past, present and future. Cell Signal. 2018;41:17–24.
Penela P, Murga C, Ribas C, Lafarga V, Mayor FJ. The complex G protein-coupled receptor kinase 2 (GRK2) interactome unveils new physiopathological targets. Br J Pharmacol. 2010;160:821–32.
Lymperopoulos A, Bathgate A. Pharmacogenomics of the heptahelical receptor regulators G-protein-coupled receptor kinases and arrestins: the known and the unknown. Pharmacogenomics. 2012;13:323–41.
Nogues L, Palacios-Garcia J, Reglero C, Rivas V, Neves M, Ribas C, et al. G protein-coupled receptor kinases (GRKs) in tumorigenesis and cancer progression: GPCR regulators and signaling hubs. Semin Cancer Biol. 2018;48:78–90.
Harris RC. Abnormalities in renal dopamine signaling and hypertension: the role of GRK4. Curr Opin Nephrol Hypertens. 2012;21:61–5.
Ribas C, Penela P, Murga C, Salcedo A, Garcia-Hoz C, Jurado-Pueyo M, et al. The G protein-coupled receptor kinase (GRK) interactome: role of GRKs in GPCR regulation and signaling. Biochim Biophys Acta. 2007;1768:913–22.
Siderovski DP, Strockbine B, Behe CI. Whither goest the RGS proteins? Crit Rev Biochem Mol Biol. 1999;34:215–51.
Clapham DE, Neer EJ. G protein beta gamma subunits. Annu Rev Pharmacol Toxicol. 1997;37:167–203.
Claing A, Laporte SA, Caron MG, Lefkowitz RJ. Endocytosis of G protein-coupled receptors: roles of G protein-coupled receptor kinases and beta-arrestin proteins. Prog Neurobiol. 2002;66:61–79.
Kohout TA, Lefkowitz RJ. Regulation of G protein-coupled receptor kinases and arrestins during receptor desensitization. Mol Pharmacol. 2003;63:9–18.
Murga C, Penela P, Ribas C, Mayor F Jr. G protein-coupled receptor kinases: specific phosphorylation of 7TM receptors and beyond. Drug Discov Today Technol. 2010;7:e1–94.
Cipolletta E, Campanile A, Santulli G, Sanzari E, Leosco D, Campiglia P, et al. The G protein coupled receptor kinase 2 plays an essential role in beta-adrenergic receptor-induced insulin resistance. Cardiovasc Res. 2009;84:407–15.
DeRita RM, Zerlanko B, Singh A, Lu H, Iozzo RV, Benovic JL, et al. c-Src, insulin-like growth factor I receptor, G-protein-coupled receptor kinases and focal adhesion kinase are enriched into prostate cancer cell exosomes. J Cell Biochem. 2017;118:66–73.
Hildreth KL, Wu JH, Barak LS, Exum ST, Kim LK, Peppel K, et al. Phosphorylation of the platelet-derived growth factor receptor-beta by G protein-coupled receptor kinase-2 reduces receptor signaling and interaction with the Na(+)/H(+) exchanger regulatory factor. J Biol Chem. 2004;279:41775–82.
Chen Y, Long H, Wu Z, Jiang X, Ma L. EGF transregulates opioid receptors through EGFR-mediated GRK2 phosphorylation and activation. Mol Biol Cell. 2008;19:2973–83.
Ho J, Cocolakis E, Dumas VM, Posner BI, Laporte SA, Lebrun JJ. The G protein-coupled receptor kinase-2 is a TGFbeta-inducible antagonist of TGFbeta signal transduction. EMBO J. 2005;24:3247–58.
Peregrin S, Jurado-Pueyo M, Campos PM, Sanz-Moreno V, Ruiz-Gomez A, Crespo P, et al. Phosphorylation of p38 by GRK2 at the docking groove unveils a novel mechanism for inactivating p38MAPK. Curr Biol. 2006;16:2042–7.
Martini JS, Raake P, Vinge LE, DeGeorge BJ, Chuprun JK, Harris DM, et al. Uncovering G protein-coupled receptor kinase-5 as a histone deacetylase kinase in the nucleus of cardiomyocytes. Proc Natl Acad Sci USA. 2008;105:12457–62.
Ferguson SS. Phosphorylation-independent attenuation of GPCR signalling. Trends Pharmacol Sci. 2007;28:173–9.
Aziziyeh AI, Li TT, Pape C, Pampillo M, Chidiac P, Possmayer F, et al. Dual regulation of lysophosphatidic acid (LPA1) receptor signalling by Ral and GRK. Cell Signal. 2009;21:1207–17.
Wang L, Gesty-Palmer D, Fields TA, Spurney RF. Inhibition of WNT signaling by G protein-coupled receptor (GPCR) kinase 2 (GRK2). Mol Endocrinol. 2009;23:1455–65.
Naga PS, Laporte SA, Chamberlain D, Caron MG, Barak L, Rockman HA. Phosphoinositide 3-kinase regulates beta2-adrenergic receptor endocytosis by AP-2 recruitment to the receptor/beta-arrestin complex. J Cell Biol. 2002;158:563–75.
Jimenez-Sainz MC, Murga C, Kavelaars A, Jurado-Pueyo M, Krakstad BF, Heijnen CJ, et al. G protein-coupled receptor kinase 2 negatively regulates chemokine signaling at a level downstream from G protein subunits. Mol Biol Cell. 2006;17:25–31.
Sallese M, Iacovelli L, Cumashi A, Capobianco L, Cuomo L, De Blasi A. Regulation of G protein-coupled receptor kinase subtypes by calcium sensor proteins. Biochim Biophys Acta. 2000;1498:112–21.
Pronin AN, Satpaev DK, Slepak VZ, Benovic JL. Regulation of G protein-coupled receptor kinases by calmodulin and localization of the calmodulin binding domain. J Biol Chem. 1997;272:18273–80.
Cong M, Perry SJ, Lin FT, Fraser ID, Hu LA, Chen W, et al. Regulation of membrane targeting of the G protein-coupled receptor kinase 2 by protein kinase A and its anchoring protein AKAP79. J Biol Chem. 2001;276:15192–9.
Mahavadi S, Huang J, Sriwai W, Rao KR, Murthy KS. Cross-regulation of VPAC2 receptor internalization by m2 receptors via c-Src-mediated phosphorylation of GRK2. Regul Pept. 2007;139:109–14.
Elorza A, Sarnago S, Mayor FJ. Agonist-dependent modulation of G protein-coupled receptor kinase 2 by mitogen-activated protein kinases. Mol Pharmacol. 2000;57:778–83.
Sarnago S, Elorza A, Mayor FJ. Agonist-dependent phosphorylation of the G protein-coupled receptor kinase 2 (GRK2) by Src tyrosine kinase. J Biol Chem. 1999;274:34411–6.
Carman CV, Lisanti MP, Benovic JL. Regulation of G protein-coupled receptor kinases by caveolin. J Biol Chem. 1999;274:8858–64.
Deiss K, Kisker C, Lohse MJ, Lorenz K. Raf kinase inhibitor protein (RKIP) dimer formation controls its target switch from Raf1 to G protein-coupled receptor kinase (GRK) 2. J Biol Chem. 2012;287:23407–17.
Nogues L, Reglero C, Rivas V, Neves M, Penela P, Mayor FJ. G-protein-coupled receptor kinase 2 as a potential modulator of the hallmarks of cancer. Mol Pharmacol. 2017;91:220–8.
Woerner BM, Luo J, Brown KR, Jackson E, Dahiya SM, Mischel P, et al. Suppression of G-protein-coupled receptor kinase 3 expression is a feature of classical GBM that is required for maximal growth. Mol Cancer Res. 2012;10:156–66.
Kaur G, Kim J, Kaur R, Tan I, Bloch O, Sun MZ, et al. G-protein coupled receptor kinase (GRK)-5 regulates proliferation of glioblastoma-derived stem cells. J Clin Neurosci. 2013;20:1014–8.
Yuan L, Zhang H, Liu J, Rubin JB, Cho YJ, Shu HK, et al. Growth factor receptor-Src-mediated suppression of GRK6 dysregulates CXCR4 signaling and promotes medulloblastoma migration. Mol Cancer. 2013;12:18.
Metaye T, Menet E, Guilhot J, Kraimps JL. Expression and activity of G protein-coupled receptor kinases in differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2002;87:3279–86.
Metaye T, Levillain P, Kraimps JL, Perdrisot R. Immunohistochemical detection, regulation and antiproliferative function of G-protein-coupled receptor kinase 2 in thyroid carcinomas. J Endocrinol. 2008;198:101–10.
Nogues L, Reglero C, Rivas V, Salcedo A, Lafarga V, Neves M, et al. G protein-coupled receptor kinase 2 (GRK2) promotes breast tumorigenesis through a HDAC6-Pin1 axis. EBioMedicine. 2016;13:132–45.
Rivas V, Carmona R, Munoz-Chapuli R, Mendiola M, Nogues L, Reglero C, et al. Developmental and tumoral vascularization is regulated by G protein-coupled receptor kinase 2. J Clin Invest. 2013;123:4714–30.
Chalakur-Ramireddy N, Pakala SB. Combined drug therapeutic strategies for the effective treatment of triple negative breast cancer. Biosci Rep. 2018;38: pii: BSR20171357. https://doi.org/10.1042/BSR20171357.
Wang C, Kar S, Lai X, Cai W, Arfuso F, Sethi G, et al. Triple negative breast cancer in Asia: An insider’s view. Cancer Treat Rev. 2018;62:29–38.
Chu QD, Panu L, Holm NT, Li BD, Johnson LW, Zhang S. High chemokine receptor CXCR4 level in triple negative breast cancer specimens predicts poor clinical outcome. J Surg Res. 2010;159:689–95.
Billard MJ, Fitzhugh DJ, Parker JS, Brozowski JM, McGinnis MW, Timoshchenko RG, et al. G protein coupled receptor kinase 3 regulates breast cancer migration, invasion, and metastasis. PLoS ONE. 2016;11:e152856.
Matsubayashi J, Takanashi M, Oikawa K, Fujita K, Tanaka M, Xu M, et al. Expression of G protein-coupled receptor kinase 4 is associated with breast cancer tumourigenesis. J Pathol. 2008;216:317–27.
King DW, Steinmetz R, Wagoner HA, Hannon TS, Chen LY, Eugster EA, et al. Differential expression of GRK isoforms in nonmalignant and malignant human granulosa cells. Endocrine. 2003;22:135–42.
Catalona WJ. Prostate cancer screening. Med Clin North Am. 2018;102:199–214.
Prowatke I, Devens F, Benner A, Grone EF, Mertens D, Grone HJ, et al. Expression analysis of imbalanced genes in prostate carcinoma using tissue microarrays. Br J Cancer. 2007;96:82–8.
Li W, Ai N, Wang S, Bhattacharya N, Vrbanac V, Collins M, et al. GRK3 is essential for metastatic cells and promotes prostate tumor progression. Proc Natl Acad Sci USA. 2014;111:1521–6.
Sang M, Hulsurkar M, Zhang X, Song H, Zheng D, Zhang Y, et al. GRK3 is a direct target of CREB activation and regulates neuroendocrine differentiation of prostate cancer cells. Oncotarget. 2016;7:45171–85.
Kim JI, Chakraborty P, Wang Z, Daaka Y. G-protein coupled receptor kinase 5 regulates prostate tumor growth. J Urol. 2012;187:322–9.
Chakraborty PK, Zhang Y, Coomes AS, Kim WJ, Stupay R, Lynch LD, et al. G protein-coupled receptor kinase GRK5 phosphorylates moesin and regulates metastasis in prostate cancer. Cancer Res. 2014;74:3489–500.
Buchanan FG, Gorden DL, Matta P, Shi Q, Matrisian LM, DuBois RN. Role of beta-arrestin 1 in the metastatic progression of colorectal cancer. Proc Natl Acad Sci USA. 2006;103:1492–7.
Wu CC, Tsai FM, Shyu RY, Tsai YM, Wang CH, Jiang SY. G protein-coupled receptor kinase 5 mediates Tazarotene-induced gene 1-induced growth suppression of human colon cancer cells. BMC Cancer. 2011;11:175.
Wei Z, Hurtt R, Ciccarelli M, Koch WJ, Doria C. Growth inhibition of human hepatocellular carcinoma cells by overexpression of G-protein-coupled receptor kinase 2. J Cell Physiol. 2012;227:2371–7.
Wei Z, Hurtt R, Gu T, Bodzin AS, Koch WJ, Doria C. GRK2 negatively regulates IGF-1R signaling pathway and cyclins’ expression in HepG2 cells. J Cell Physiol. 2013;228:1897–901.
Xu ZW, Yan SX, Wu HX, Chen JY, Zhang Y, Li Y, et al. The influence of TNF-alpha and Ang II on the proliferation, migration and invasion of HepG2 cells by regulating the expression of GRK2. Cancer Chemother Pharmacol. 2017;79:747–58.
Ma Y, Han CC, Huang Q, Sun WY, Wei W. GRK2 overexpression inhibits IGF1-induced proliferation and migration of human hepatocellular carcinoma cells by downregulating EGR1. Oncol Rep. 2016;35:3068–74.
Buchholz M, Honstein T, Kirchhoff S, Kreider R, Schmidt H, Sipos B, et al. A multistep high-content screening approach to identify novel functionally relevant target genes in pancreatic cancer. PLoS ONE. 2015;10:e122946.
Zhou L, Wang MY, Liang ZY, Zhou WX, You L, Pan BJ, et al. G-protein-coupled receptor kinase 2 in pancreatic cancer: clinicopathologic and prognostic significance. Hum Pathol. 2016;56:171–7.
Raghuwanshi SK, Smith N, Rivers EJ, Thomas AJ, Sutton N, Hu Y, et al. G protein-coupled receptor kinase 6 deficiency promotes angiogenesis, tumor progression, and metastasis. J Immunol. 2013;190:5329–36.
Yao S, Zhong L, Liu J, Feng J, Bian T, Zhang Q, et al. Prognostic value of decreased GRK6 expression in lung adenocarcinoma. J Cancer Res Clin Oncol. 2016;142:2541–9.
Sanchez-Mas J, Guillo LA, Zanna P, Jimenez-Cervantes C, Garcia-Borron JC. Role of G protein-coupled receptor kinases in the homologous desensitization of the human and mouse melanocortin 1 receptors. Mol Endocrinol. 2005;19:1035–48.
Perez-Sayans M, Somoza-Martin JM, Barros-Angueira F, Gayoso-Diz P, Otero-Rey EM, Gandra-Rey JM, et al. Activity of beta2-adrenergic receptor in oral squamous cell carcinoma is mediated by overexpression of the ADRBK2 gene: a pilot study. Biotech Histochem. 2012;87:179–86.
Tiedemann RE, Zhu YX, Schmidt J, Yin H, Shi CX, Que Q, et al. Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6. Blood. 2010;115:1594–604.
Hu M, Wang C, Li W, Lu W, Bai Z, Qin D, et al. A KSHV microRNA directly targets G protein-coupled receptor kinase 2 to promote the migration and invasion of endothelial cells by inducing CXCR2 and activating AKT signaling. PLoS Pathog. 2015;11:e1005171.
Geras-Raaka E, Arvanitakis L, Bais C, Cesarman E, Mesri EA, Gershengorn MC. Inhibition of constitutive signaling of Kaposi’s sarcoma-associated herpesvirus G protein-coupled receptor by protein kinases in mammalian cells in culture. J Exp Med. 1998;187:801–6.
Chen X, Zhu H, Yuan M, Fu J, Zhou Y, Ma L. G-protein-coupled receptor kinase 5 phosphorylates p53 and inhibits DNA damage-induced apoptosis. J Biol Chem. 2010;285:12823–30.
Acknowledgements
This work was supported by grants from the National Natural Science Foundation of China (No. 81770605, 81300332), the Natural Science Foundation of the Higher Education Institutions of Anhui Province (No. gxyqZD2018024, KJ2018A0200) and the Natural Science Foundation of Anhui Medical University (No. 2017xkj032). The authors acknowledge the help of the staff members of the Institute of Clinical Pharmacology, Anhui Medical University.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Sun, Wy., Wu, Jj., Peng, Wt. et al. The role of G protein-coupled receptor kinases in the pathology of malignant tumors. Acta Pharmacol Sin 39, 1699–1705 (2018). https://doi.org/10.1038/s41401-018-0049-z
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/s41401-018-0049-z
Keywords
This article is cited by
-
Unveiling G-protein coupled receptors as potential targets for ovarian cancer nanomedicines: from RNA sequencing data analysis to in vitro validation
Journal of Ovarian Research (2024)
-
Transcriptome signatures of host tissue infected with African swine fever virus reveal differential expression of associated oncogenes
Archives of Virology (2024)
-
Computational analysis of G-protein-coupled receptor kinase family members as potential targets for colorectal cancer therapy
Egyptian Journal of Medical Human Genetics (2022)
-
G protein-coupled receptor kinase 2 modifies the cellular reaction to cisplatin through interactions with NADPH oxidase 4
Molecular and Cellular Biochemistry (2021)
